AG Kokott: GSK pay-for-delay agreements “may be” abusive

GlaxoSmithKline may have abused its dominant position when it signed pay-for-delay agreements with three generic drugmakers, an advocate general to the European Court of Justice has said.

Get unlimited access to all Global Competition Review content